FLT3 and acute myeloid leukemia: Because midostaurin exerts additional non-FLT3 kinase inhibitory activity, we sought to reproduce this effect with the more selective and potent FLT3 inhibitor gilteritinib, which has enhanced in vivo activity and monotherapy activity in patients with AML [24].